Investigating Phenotypic Changes in Response to Drug Treatments in Epithelial Ovarian Cancer Using a Novel Si-TiB2 Micropatterned Substrate

Simple item page
dc.contributor.advisorMerchant, Fatima Aziz
dc.contributor.advisorMajd, Sheereen
dc.contributor.committeeMemberZagozdzon-Wosik, Wanda
dc.contributor.committeeMemberAl-Ubaidi, Muayyad R.
dc.creatorEisenbrandt, Margaret Ruth
dc.creator.orcid0000-0002-0190-1922
dc.date.accessioned2022-12-30T03:06:38Z
dc.date.createdMay 2022
dc.date.issued2022-05-10
dc.date.updated2022-12-30T03:06:39Z
dc.description.abstractEpithelial ovarian cancer (EOC) is one of the most prevalent cancers in women worldwide, with nearly 80% of cases diagnosed in late-stage of disease and an overall survival rate of less than 50%. 3D culture is necessary in order to study the in vivo response of cancer cells to therapeutic agents, in systems that better mimic innate cell-cell and cell-ECM interactions. This study evaluates the potential of a novel micropatterned substrate, fabricated using photolithography to deposit TiB2 micropatterns onto a Si wafer to study the response of EOC to epigenetic and chemotherapeutic drugs. Previous work has validated that the Si-TiB2 substrate enables selective deposition of growth factors and self-assembly of cells onto the TiB2 pattern through differences in stiffness, roughness, wetness, and charge gradient. For EOC cell lines, OVCAR3 (low invasiveness) and SKOV3 (high invasiveness), the Si-TiB2 micropatterned substrate supported cell proliferation and maintained viability, and 3D aggregation for SKOV3 cells. Treating SKOV3 aggregates and OVCAR3 monolayers on patterned substrates, with an epigenetic drug, vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), resulted in decreased diameter and thickness, however viability of the remaining cells was unchanged. Genomic analysis of the treated aggregates suggests a change in phenotype of SKOV3 after treatment with SAHA. While studies show that SAHA alone may not be a sufficient treatment for EOC, it does have the potential to augment the treatment of some cancers when used in combination with chemotherapeutic agents. Treatment of SKOV3 aggregates with a combination of SAHA and Paclitaxel was shown to decrease proliferation and halt growth for an extended period after treatment however these results are not statistically different from the Paclitaxel treatment group, which agrees with a clinical trial of SAHA and Paclitaxel combinatorial treatment. Collectively, data support use of the micropatterned substrate for investigation of potential drug therapies for cancer treatment and cellular changes in response to drug treatment.
dc.description.departmentBiomedical Engineering, Department of
dc.format.digitalOriginborn digital
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/10657/13164
dc.language.isoeng
dc.rightsThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).
dc.subjectTissue Engineering
dc.subjectOvarian Cancer
dc.subject3D model
dc.subjectSubstrate
dc.subjectCell Biology
dc.titleInvestigating Phenotypic Changes in Response to Drug Treatments in Epithelial Ovarian Cancer Using a Novel Si-TiB2 Micropatterned Substrate
dc.type.dcmiText
dc.type.genreThesis
dcterms.accessRightsThe full text of this item is not available at this time because the student has placed this item under an embargo for a period of time. The Libraries are not authorized to provide a copy of this work during the embargo period.
local.embargo.lift2024-05-01
local.embargo.terms2024-05-01
thesis.degree.collegeCullen College of Engineering
thesis.degree.departmentBiomedical Engineering, Department of
thesis.degree.disciplineBiomedical Engineering
thesis.degree.grantorUniversity of Houston
thesis.degree.levelMasters
thesis.degree.nameMaster of Science in Biomedical Engineering

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
EISENBRANDT-THESIS-2022.pdf
Size:
3.92 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.44 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.82 KB
Format:
Plain Text
Description:
Download

Collections

Published ETD Collection